Loading patent…
AssigneeWyeth
InventorsManinder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Terri L. Mininni, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
Estimating the term…
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
An immunogenic composition comprising an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:
An immunogenic composition comprising an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:
An immunogenic composition comprising an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.